JP2025121906A5 - - Google Patents

Info

Publication number
JP2025121906A5
JP2025121906A5 JP2025065457A JP2025065457A JP2025121906A5 JP 2025121906 A5 JP2025121906 A5 JP 2025121906A5 JP 2025065457 A JP2025065457 A JP 2025065457A JP 2025065457 A JP2025065457 A JP 2025065457A JP 2025121906 A5 JP2025121906 A5 JP 2025121906A5
Authority
JP
Japan
Prior art keywords
effector protein
sequence
cas9 effector
guide
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025065457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025121906A (ja
Filing date
Publication date
Priority claimed from JP2020526198A external-priority patent/JP7423520B2/ja
Application filed filed Critical
Publication of JP2025121906A publication Critical patent/JP2025121906A/ja
Publication of JP2025121906A5 publication Critical patent/JP2025121906A5/ja
Pending legal-status Critical Current

Links

JP2025065457A 2017-11-16 2025-04-11 Cas9ベースノックイン方針の効力を改善するための組成物及び方法 Pending JP2025121906A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762587029P 2017-11-16 2017-11-16
US62/587,029 2017-11-16
US201862693690P 2018-07-03 2018-07-03
US62/693,690 2018-07-03
JP2020526198A JP7423520B2 (ja) 2017-11-16 2018-11-16 Cas9ベースノックイン方針の効力を改善するための組成物及び方法
PCT/US2018/061680 WO2019099943A1 (en) 2017-11-16 2018-11-16 Compositions and methods for improving the efficacy of cas9-based knock-in strategies
JP2024005210A JP7703707B2 (ja) 2017-11-16 2024-01-17 Cas9ベースノックイン方針の効力を改善するための組成物及び方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2024005210A Division JP7703707B2 (ja) 2017-11-16 2024-01-17 Cas9ベースノックイン方針の効力を改善するための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2025121906A JP2025121906A (ja) 2025-08-20
JP2025121906A5 true JP2025121906A5 (https=) 2025-08-29

Family

ID=64870555

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020526198A Active JP7423520B2 (ja) 2017-11-16 2018-11-16 Cas9ベースノックイン方針の効力を改善するための組成物及び方法
JP2024005210A Active JP7703707B2 (ja) 2017-11-16 2024-01-17 Cas9ベースノックイン方針の効力を改善するための組成物及び方法
JP2025065457A Pending JP2025121906A (ja) 2017-11-16 2025-04-11 Cas9ベースノックイン方針の効力を改善するための組成物及び方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020526198A Active JP7423520B2 (ja) 2017-11-16 2018-11-16 Cas9ベースノックイン方針の効力を改善するための組成物及び方法
JP2024005210A Active JP7703707B2 (ja) 2017-11-16 2024-01-17 Cas9ベースノックイン方針の効力を改善するための組成物及び方法

Country Status (5)

Country Link
US (2) US20210180059A1 (https=)
EP (1) EP3710583A1 (https=)
JP (3) JP7423520B2 (https=)
CN (2) CN111448313A (https=)
WO (1) WO2019099943A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637739B2 (en) * 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
WO2018119010A1 (en) 2016-12-19 2018-06-28 Editas Medicine, Inc. Assessing nuclease cleavage
EP3565907B1 (en) 2017-01-06 2022-05-04 Editas Medicine, Inc. Methods of assessing nuclease cleavage
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
WO2018227114A1 (en) 2017-06-09 2018-12-13 Editas Medicine, Inc. Engineered cas9 nucleases
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
KR20210045360A (ko) 2018-05-16 2021-04-26 신테고 코포레이션 가이드 rna 설계 및 사용을 위한 방법 및 시스템
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
US11530425B2 (en) 2019-10-09 2022-12-20 Massachusetts Institute Of Technology Systems, methods, and compositions for correction of frameshift mutations
CN115427566A (zh) * 2020-04-08 2022-12-02 阿斯利康(瑞典)有限公司 用于改善的位点特异性修饰的组合物和方法
JP2023540427A (ja) * 2020-07-07 2023-09-25 オリエンジーン バイオテクノロジー リミテッド Hsv-1遺伝子編集のためのガイドrnaおよびその方法
CN114438235A (zh) * 2020-11-04 2022-05-06 深圳市南山区疾病预防控制中心 一种同时检测嗜低温弓形杆菌及斯氏弓形杆菌的引物探针组件、试剂盒及其应用
JP2024513087A (ja) * 2021-04-07 2024-03-21 アストラゼネカ・アクチエボラーグ 部位特異的改変のための組成物及び方法
CN117396602A (zh) 2021-05-27 2024-01-12 阿斯利康(瑞典)有限公司 具有增强的稳定性的cas9效应蛋白
CN113481184A (zh) * 2021-08-06 2021-10-08 北京大学 融合蛋白以及其使用方法
WO2023052508A2 (en) 2021-09-30 2023-04-06 Astrazeneca Ab Use of inhibitors to increase efficiency of crispr/cas insertions
CN118715317A (zh) * 2021-12-15 2024-09-27 武汉大学 Dna聚合酶介导的基因组编辑
CN121127605A (zh) 2023-03-29 2025-12-12 阿斯利康(瑞典)有限公司 使用抑制剂来提高CRISPR/Cas插入的效率
CN119614679A (zh) * 2023-09-14 2025-03-14 厦门大学 一款通用型核酸检测平台
CN116949012B (zh) * 2023-09-20 2024-01-02 广州瑞风生物科技有限公司 一种融合蛋白及其应用
EP4678742A1 (en) 2024-07-10 2026-01-14 Astrazeneca AB Improved cas9 proteins

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5895309A (en) 1998-02-09 1999-04-20 Spector; Donald Collapsible hula-hoop
JP2008078613A (ja) 2006-08-24 2008-04-03 Rohm Co Ltd 窒化物半導体の製造方法及び窒化物半導体素子
ES2646630T3 (es) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Lipidoides aminoalcohólicos y usos de los mismos
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology POLY (BETA AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
KR102530118B1 (ko) 2012-07-25 2023-05-08 더 브로드 인스티튜트, 인코퍼레이티드 유도 dna 결합 단백질 및 게놈 교란 도구 및 이의 적용
WO2014033644A2 (en) 2012-08-28 2014-03-06 Novartis Ag Methods of nuclease-based genetic engineering
EP3363902B1 (en) 2012-12-06 2019-11-27 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
CA2894684A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
CN105121648B (zh) * 2012-12-12 2021-05-07 布罗德研究所有限公司 用于序列操纵的系统、方法和优化的指导组合物的工程化
DK2931897T3 (en) 2012-12-12 2018-02-05 Broad Inst Inc CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
AU2014227653B2 (en) 2013-03-15 2017-04-20 The General Hospital Corporation Using RNA-guided foki nucleases (RFNs) to increase specificity for RNA-guided genome editing
EP3778899A1 (en) 2013-05-22 2021-02-17 Northwestern University Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis
EP3011030B1 (en) 2013-06-17 2023-11-08 The Broad Institute, Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
WO2015089364A1 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
EP3470089A1 (en) * 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
BR112016013207A2 (pt) * 2013-12-12 2017-09-26 Massachusetts Inst Technology administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para o hbv e distúrbios e doenças virais
ES2730378T3 (es) * 2014-08-27 2019-11-11 Caribou Biosciences Inc Procedimientos para incrementar la eficiencia de la modificación mediada por Cas9
US10858662B2 (en) 2014-11-19 2020-12-08 Institute For Basic Science Genome editing with split Cas9 expressed from two vectors
WO2016106236A1 (en) * 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
EP3250691B9 (en) 2015-01-28 2023-08-02 Caribou Biosciences, Inc. Crispr hybrid dna/rna polynucleotides and methods of use
EP3303634B1 (en) * 2015-06-03 2023-08-30 The Regents of The University of California Cas9 variants and methods of use thereof
WO2016205759A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US20180201912A1 (en) * 2015-07-14 2018-07-19 The University Of Tokyo Modified fncas9 protein and use thereof
US11479793B2 (en) * 2015-07-15 2022-10-25 Rutgers, The State University Of New Jersey Nuclease-independent targeted gene editing platform and uses thereof
WO2017151444A1 (en) * 2016-02-29 2017-09-08 Agilent Technologies, Inc. Methods and compositions for blocking off-target nucleic acids from cleavage by crispr proteins
EP3699281A1 (en) * 2016-03-11 2020-08-26 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
CA3010628A1 (en) * 2016-03-11 2017-09-14 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
US20200263190A1 (en) * 2016-04-19 2020-08-20 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2017189336A1 (en) * 2016-04-25 2017-11-02 The Regents Of The University Of California Methods and compositions for genomic editing
CN116850305A (zh) * 2016-05-06 2023-10-10 朱诺治疗学股份有限公司 基因工程化细胞及其制备方法

Similar Documents

Publication Publication Date Title
JP2025121906A5 (https=)
US20230383290A1 (en) High-throughput precision genome editing
CN111836894B (zh) 用于使用CRISPR/Cpf1系统进行基因组编辑的组合物及其用途
ES2950736T3 (es) Vectores de nanoplásmidos virales y no virales con una producción mejorada
CN113015798B (zh) CRISPR-Cas12a酶和系统
KR20200036025A (ko) 메신저 리보핵산(mRNA)을 암호화하는 안정화된 핵산
JPH11500618A (ja) Dna分子、その製造及び遺伝子治療における使用
JP2017505117A (ja) 多重ガイドrna
JPWO2021050571A5 (https=)
RU2018101666A (ru) Новые ферменты и системы crispr
JP2022023144A5 (https=)
RU2022103641A (ru) Искусственная модификация генома для регуляции экспрессии гена
JP2004503207A (ja) 核酸をライゲーションする方法および分子クローニング
CN107164375B (zh) 一种新型向导RNA表达盒及在CRISPR/Cas系统中的应用
WO2023098485A1 (zh) 一种基于c2c9核酸酶的新型基因组编辑系统及其应用
JP2024116193A5 (https=)
US20250243515A1 (en) Nucleases and compositions, systems, and methods thereof
JPWO2021102390A5 (https=)
JP7361109B2 (ja) C2c1ヌクレアーゼに基づくゲノム編集のためのシステムおよび方法
WO2024125221A1 (zh) 一种碱基编辑系统及碱基编辑方法
JPWO2023169410A5 (https=)
US20250179454A1 (en) Fusion proteins and uses thereof for precision editing
CN110551762B (zh) CRISPR/ShaCas9基因编辑系统及其应用
JP4465741B2 (ja) 二本鎖dna断片の末端での連結
CN117987464A (zh) 一种供体构建体、用于修饰细胞基因组的组合物及修饰细胞基因组的方法